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Abstract
Influenza viruses are classified based on their surface
glycoproteins: hemagglutinin and neuraminidase.
Hemagglutinin (HA) is responsible for binding to the host cell,
while neuraminidase (NA) facilitates escape of newly formed
virus particles. These studies determined the NA activity of three
subtypes of influenza A virus that differ in their ability to cause
disease in mice: influenza A/NWS/33 (H1N1), influenza A/
Victoria/3/75 (H3N2), and influenza A/Duck/MN/1525/81
(H5N1). Chemiluminescent quantitation of NA activity in equal
amounts of each virus was determined in three replicate
experiments. Results indicate that N1 virus subtypes have
higher NA activity than do N2 subtypes. In addition, the NA
activity of each virus was tested in the presence of the NA
inhibitor oseltamivir. Effective antiviral concentrations of
oseltamivir for each virus were EC50 = 0.51, 0.19, and 0.70 nM
for NWS, Victoria, and Duck viruses, respectively. These results
do not support the hypothesis that NA activity alone determines
the ability of the virus to cause disease. However, these data do
suggest a correlation between NA activity and virus resistance to
oseltamivir.

Figure 1: A model of the influenza virus [5].

Introduction
Neuraminidase activity is critical for the virus to release itself
from infected cells [1]. This in turn will cause subsequent virus
spread. NA has also been proposed to aid in the entry of the
virus into target cells [2]. This occurs during the initial stages of
infection. The roles of NA in influenza are important for its
success and ability to cause disease. A focus of current
chemotherapeutic treatment regimens involve inhibiting the
activity of the NA enzyme. These antiviral drugs are called
neuraminidase inhibitors. Oseltamivir, zanamivir, and peramivir
are used and studied today. Influenza has shown an incredible
increase of resistance to oseltamivir. In the 2007 - 2008 winter,
the virus tested positive for resistance 11% of the time from
throat swabs of patients with the most common influenza
subtype [3]. Since then, the resistance of the virus has been
increasing.

Methods

Results

Virus subtypes and the NA inhibitor, Oseltamivir, were provided
by the Institute for Antiviral Research. The virus stocks used
were Influenza A/NWS/33 (H1N1), influenza A/Victoria/3/75
(H3N2), and influenza A/Duck/MN/1525/81 (H5N1). In each
test, virus subtypes were used at equal titers and run in triplicate.
The effect of oseltamivir on viral neuraminidase activity was
performed using a commercially available kit (NA-Star®
Influenza Neuraminidase Inhibitor Resistance Detection Kit,
Applied Biosystems, Foster City, CA) in 96-well solid white
microplates following the manufacturer’s instructions [4,6].
Oseltamivir in half-log dilution increments was incubated with
virus (as the source of neuraminidase). The amount of virus in
each microwell was approximately 500 cell culture infectious
doses (CCID50). Plates were pre-incubated for 20 minutes at
37oC prior to addition of chemiluminescent substrate. Following
addition of substrate plates were incubated for 30 minutes at
37oC. The neuraminidase activity was evaluated using a Centro
LB 960 luminometer (Berthold Technologies) for 0.5 seconds
immediately after addition of NA-Star® accelerator solution.
Fifty percent virus-inhibitory concentrations (EC50 values) of
viral neuraminidase activity were determined by plotting percent
chemiluminescent counts versus log10 of oseltamivir
concentration. NA activity of each virus subtype was determined
by completing the assay using only buffer.
Antiviral activity of oseltamivir carboxylate, the active form of
oseltamivir, was determined in Madin-Darby canine kidney
(MDCK) cells. The cells were grown in MEM supplemented
with 5% FBS. The assays were completed in 96-well
microplates infected with approximately 50 CCID50 of virus.
Microplates were visually examined after 3 days of infection and
then treated for 1.5 hours with neutral red (0.011% final
concentration) to quantify the virus-induced cytopathic effects
(CPE). Excess dye was rinsed from cells with PBS. The
absorbed dye was eluted from the cells by addition of 0.1 ml of
50% Sorensen’s citrate buffer/50% ethanol to each well. Optical
density (OD) measurements were completed on the microtiter
plates at 560 nm. OD readings were converted to percent of
uninfected control using an Excel spread sheet developed for this
purpose. EC50 values were determined by plotting percent CPE
versus log10 of inhibitor concentration.
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Figure 3:
Neuraminidase
activity graphed as
percent
chemiluminescence
vs oseltamivir
concentration in nM.

The virus titers were 1 x 10 4.8, 1 x 10 6.3, and 1 x 10 6.4 PFU/ml
for NWS, Victoria, and Duck viruses respectively. Virus titers
were equalized using dilutions. The dilutions used were 1:5,
1:90, and 1:90 for NWS, Victoria, and Duck viruses, respectively.
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Figure 2:
Neuraminidase activity
of each virus subtype
tested at equal virus
concentrations.
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Shown by Figure 2, NA activity levels at equal concentrations of
virus indicate that the N1 subtype has a higher NA activity than
does the N2 subtype. Additional testing of several other
influenza virus subtypes have corroborated these data.
Figure 3 shows the dose-response curve of each of the viruses in
the presence of oseltamivir. Effective concentration values of
oseltamivir for each virus subtype were EC50 = 0.51, 0.19, and
0.70 nM for NWS, Victoria, and Duck viruses, respectively.
These data indicate that the Duck virus is more resistant to
oseltamivir than is the NWS or the Victoria viruses. The NWS
virus is more resistant than is the Victoria virus. A virus
expressing resistance is one that requires a higher concentration
of oseltamivir to inhibit the NA activity. These data also indicate
that a higher concentration of oseltamivir than was used in these
assays would be required for complete inhibition of NA activity
for the Duck virus.
Results shown in Figure 4 are the mean and standard deviation of
four replicates of in vitro testing in MDCK cells. The visual
observation indicates that a higher concentration of oseltamivir is
required to inhibit the Duck virus compared to the NWS virus
and the Victoria virus.
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Figure 4: In Vitro Testing Results in MDCK cells

These studies conclude that NA subtype one (N1) has a higher
NA activity comparative to NA subtype two (N2). The Duck
virus is most resistant to oseltamivir in the NA-Star® assay and
in cell culture studies. These data suggest there is correlation
between NA activity and virus resistance to oseltamivir. This
research will hopefully lead to better ways of identifying drugresistant influenza virus strains.
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